

Article

An *ABCC9* Missense Variant Is Associated with Sudden Cardiac Death and Dilated Cardiomyopathy in Juvenile Dogs

Eva Furrow ^{1,*} , Nicole Tate ¹, Katie Minor ¹ , Shannon Martinson ², Shannon Larrabee ¹, Marjukka Anttila ³, Meg Sleeper ⁴ and Paula Henthorn ⁵

¹ College of Veterinary Medicine, University of Minnesota, St. Paul, MN 55455, USA

² Atlantic Veterinary College, University of Prince Edward Island, Charlottetown, PE CIA 4P3, Canada

³ Pathology, Finnish Food Authority, 00790 Helsinki, Finland

⁴ College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA

⁵ School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

* Correspondence: furro004@umn.edu

Abstract: Sudden cardiac death in the young (SCDY) is a devastating event that often has an underlying genetic basis. Manchester Terrier dogs offer a naturally occurring model of SCDY, with sudden death of puppies as the manifestation of an inherited dilated cardiomyopathy (DCM). We performed a genome-wide association study for SCDY/DCM in Manchester Terrier dogs and identified a susceptibility locus harboring the cardiac ATP-sensitive potassium channel gene *ABCC9*. Sanger sequencing revealed an *ABCC9* p.R1186Q variant present in a homozygous state in all SCDY/DCM-affected dogs ($n = 26$). None of the controls genotyped ($n = 398$) were homozygous for the variant, but 69 were heterozygous carriers, consistent with autosomal recessive inheritance with complete penetrance ($p = 4 \times 10^{-42}$ for the association of homozygosity for *ABCC9* p.R1186Q with SCDY/DCM). This variant exists at low frequency in human populations (rs776973456) with clinical significance previously deemed uncertain. The results of this study further the evidence that *ABCC9* is a susceptibility gene for SCDY/DCM and highlight the potential application of dog models to predict the clinical significance of human variants.

Keywords: channelopathy; canine; sudden cardiac death in the young; molecular autopsy



Citation: Furrow, E.; Tate, N.; Minor, K.; Martinson, S.; Larrabee, S.; Anttila, M.; Sleeper, M.; Henthorn, P. An *ABCC9* Missense Variant Is Associated with Sudden Cardiac Death and Dilated Cardiomyopathy in Juvenile Dogs. *Genes* **2023**, *14*, 988. <https://doi.org/10.3390/genes14050988>

Academic Editor: Benjamin N. Sacks

Received: 6 April 2023

Revised: 23 April 2023

Accepted: 26 April 2023

Published: 27 April 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Molecular autopsies for sudden cardiac death in the young (SCDY) reveal pathogenic or likely pathogenic variants in 6–29% of cases [1–5]. The rate of molecular diagnosis of dilated cardiomyopathy (DCM) is similar [6]. Identification of susceptibility variants for SCDY and DCM increases diagnostic rates and enables screening of family members. However, validation of candidate genes and prediction of pathogenicity for specific variants is complicated by inability to perform segregation analyses in most families, due to only one or few affected individuals [3,4,7–9]. As such, many of the candidate genes for SCDY and DCM lack strong evidence of disease association [9–11]. Canine models offer unique advantages for validating disease-associated genes and variants. Due to population bottlenecks from limited founders and selective breeding, individual dog breeds have relatively little genetic diversity with disease traits often controlled by a small number of pathogenic variants [12]. This population structure is advantageous for the identification of disease-associated genes and variants. Dogs share susceptibility genes for many inherited diseases with humans, including sudden cardiac death and DCM [13–16]. Research in dogs has also identified novel susceptibility genes for sudden cardiac death and DCM [17–19]. Thus, canine models can be used to better understand molecular contributions to SCDY/DCM in humans and inform development and interpretation of molecular gene panels.

The Manchester Terrier provides a naturally occurring animal model of SCDY/DCM with disease manifesting as sudden death before 2 years of age, typically by 6 months [20]. Necropsy findings support acute and chronic forms. In the acute form, the heart is macroscopically normal with histopathologic abnormalities of acute multifocal myocardial degeneration and necrosis without inflammation. In the chronic form, mild cardiomegaly, left ventricle dilation, left ventricular wall thickening, and left auricle enlargement are common; in addition to myocardial degeneration, histopathologic abnormalities include myocardial fibrosis, mild inflammation, and, less frequently, myocardial mineralization. Dogs appear healthy prior to sudden death, with reports of anesthetic events or exercise preceding death in some cases [20].

In this study, we sought to discover the susceptibility gene for SCDY/DCM in Manchester Terrier dogs. We report results of a genome-wide association study (GWAS), sequencing of positional candidate genes, and follow-up genotyping of a putative causal variant for SCDY/DCM.

2. Materials and Methods

2.1. Study Population

Purebred Manchester Terrier dogs were enrolled in the initial study cohort, used for the GWAS. This GWAS cohort comprised 48 Manchester Terriers, including 12 cases and 36 controls. The 12 cases were dogs that passed away suddenly before 2 years of age and were confirmed to have DCM by postmortem histopathology characterized by foci of myocardial degeneration with fibrosis and mild lymphoplasmacytic infiltrates (Figure 1); 10 of the 12 dogs were included in a previous study on the histological characterization of the disease [20]. The average age at the time of death was 6 ± 4 months (range 2–14 months). The case population included seven female dogs and five male dogs; four of the five male dogs were reported to be unilaterally or bilaterally cryptorchid, and the reproductive status for the fifth male was not reported. The GWAS controls comprised 36 dogs of at least 2 years of age (average 8.0 ± 4.1 years, range 2–15 years) and unrelated within two generations; the controls included 20 females and 16 males, none of which were cryptorchid.

Additional dogs were included in follow up genotyping to validate the association of a variant of interest with SCDY/DCM. Both Manchester Terriers and English Toy Terriers were recruited during this study phase. These are closely related breeds with similar appearances (Figure 2), and pedigrees for some study dogs contained both breeds. The final study population comprised 19 cases with SCDY with or without pathologic confirmation of DCM (15 Manchester Terriers and 4 English Toy Terriers), 398 controls ≥ 2 years old without known heart disease (225 Manchester Terriers and 173 English Toy Terriers), 401 unknowns < 2 years old without known heart disease (194 Manchester Terriers and 207 English Toy Terriers), and 3 with other cardiac disease (English Toy Terriers with hypertrophic cardiomyopathy). Dogs in the unknown phenotype group were followed into adulthood (2 years of age or beyond) to determine their outcomes, and 7 additional dogs were diagnosed with SCDY/DCM (total of 26 cases). The study protocol was approved by the University of Minnesota Institutional Animal Care and Use Committee (protocol ID 1509-33019A), and written informed consent was obtained from dog owners. Paraffin-embedded tissue (for deceased dogs), whole blood (3–4 mL in an EDTA tube), or cheek swab samples were collected from each dog. DNA was extracted using the Puregene Blood Kit (Qiagen) following manufacturer instructions. Extracted DNA was stored at -20°C prior to genotyping.




Figure 1. Right ventricle from a juvenile Manchester Terrier showing patchy regions of pallor in the myocardium (arrows). HE, scale = 200 μm . Upper inset: In these areas, there is myofiber degeneration and loss with replacement by connective tissue and scant mononuclear cells. Degenerate myofibers are present in the upper right half of the inset and are small (attenuated) with flocculent cytoplasm. Normal myofibers are evident at the lower right corner for comparison. HE, scale = 20 μm . Lower inset: Staining with Masson's trichrome demonstrates collagen deposition (blue) in the affected regions. Scale = 20 μm .




Figure 2. Photographs of two closely related dog breeds affected by sudden cardiac death of the young and dilated cardiomyopathy: (a) Manchester Terrier dog; (b) English Toy Terrier dog.

2.2. SNP Genotyping and Analysis

SNP genotyping was performed with the Illumina CanineHD BeadChip (173,931 SNPs). Genotype quality control measures were performed using PLINK v1.90b3.30 (RRID SCR_001757) [21], a whole genome analysis toolset, and included exclusion of SNPs with genotyping calls <90% (11,937 SNPs removed), SNPs with a minor allele fre-

quency <5% (68,520 SNPs removed), SNPs with differential missingness between cases and controls at $p \leq 0.01$ (1297 SNPs removed), and SNPs that reject the hypothesis of Hardy–Weinberg equilibrium in the control population at $p \leq 0.001$ (218 SNPs removed). The final dataset of 91,959 SNPs was analyzed with a linear mixed model implemented in GEMMA version 0.94.1 to control for population stratification [22]. p -values were calculated with the Wald test. R software for statistical computing was used to generate plots (R version 4.1.0, <http://www.R-project.org/>, accessed on 10 June 2021). Population stratification was assessed by calculating the genomic inflation factor from the p -value distribution.

2.3. Haplotype Analysis and Sequencing

Haplotypes for the region encompassing the top SNPs (29 with $p < 10^{-8}$) were inferred from the SNP genotype data with the fastPHASE program version 1.2.3 [23]. The critical region was defined by where all 12 cases from the GWAS were homozygous for a shared haplotype. One of the cases was selected for Sanger sequencing of two positional candidate genes, *ABCC9* and *KCNJ8* (primers provided in Table S1).

2.4. Variant Selection, Genotyping, and Association with SCDY/DCM

Genomic variant locations were determined through a BLAT search (RRID SCR_011919) of the Dog10K_Boxer_Tasha/canFam6 assembly (GenBank assembly accession GCA_000002285.4) for 35–45 bases of the variant-containing sequence [24,25]. Transcript ENSCAFT00000043641.4 and UniProt J9NYX2 were used to determine the variant position and effect on the protein sequence for *ABCC9*, and ENSCAFT00000049622.3 and UniProt J9NU52 were used for *KCNJ8*. If the variant was a known single nucleotide polymorphism in dogs, the allele frequency was determined based on data in dbSNP *Canis lupus familiaris* build 151 [26]. Variant allele frequency was also determined in the Dog Biomedical Variant Database Consortium database of whole genome sequencing variant calls from 813 dogs (137 breeds and 9 wolves) [27].

Two in silico programs, PolyPhen-2 (RRID SCR_013189) and MutPred2 (RRID SCR_010778), were used to predict pathogenicity for missense variants [28,29]. For PolyPhen-2, the HumVar model was used because it is recommended for Mendelian diseases [28]. The University of California Santa Cruz Genome Browser was used to convert variant positions in the canine assembly to the position for the homologous nucleotide in the human assembly GRCh38/hg38 [30]. Nucleotide conservation scores were determined for variants using the “100 Vertebrates Basewise Conservation by phyloP (phyloP100way)” track on the UCSC Genome Browser [31]. PhyloP scores are the $-\log_{10}$ (p value) for rejecting the null hypothesis of neutral evolution; positive scores indicate conservation. The frequency of homologous human variants was determined using dbSNP *Homo sapiens* build 155. The AlphaFold Protein Structure Database was searched to identify the *ABCC9* predicted protein structure [32,33]. The human UniProt entry O60706-F1 was used for structure prediction because the only canine UniProt entry with a prediction, A0A5F4DDH2-F1, was incomplete with only 149 of the 1549 amino acids. PyMOL Version 2.5.5 (RRID SCR_000305) was used for visualizing the location of an *ABCC9* missense variant [34], and Missense3D was used to predict structural changes using the AlphaFold model [35].

The putative pathogenic variant was genotyped in the full cohort of 821 dogs using Sanger sequencing of PCR products spanning the variants (Table S1) or custom TaqMan SNP Genotyping Assay (Assay ID: ANAAPHA, Thermo Fisher Scientific Inc., Waltham, MA, USA). A chi-square test was used to test the association between SCDY/DCM and a homozygous genotype for the putative pathogenic variant.

3. Results

3.1. Discovery of an *ABCC9* Missense Variant in a Natural Canine Model of SCDY/DCM

The GWAS of 48 Manchester Terrier dogs (12 SCDY/DCM cases and 36 controls) revealed a strong signal on CFA27 ($p = 5 \times 10^{-17}$, genomic inflation factor = 1.2; Figures 3, S1 and S2, and Table S2). The most strongly associated haplotype spanned 1.9 Mb (CFA27 g.24710989–26639517 bp, Broad CanFam3.1/canFam3; CFA27 g.19817148–21651279

bp, Dog10K_Boxer_Tasha/canFam6) and contains 25 protein-coding genes (Table S3). All cases and no controls were homozygous for the risk haplotype in this region.




Figure 3. Manhattan plot of a mixed model genome-wide association study for sudden cardiac death in the young and dilated cardiomyopathy in 12-case and 36-control Manchester Terrier dogs. There is a strong signal on chromosome 27 ($p = 5 \times 10^{-17}$ Wald test) at a locus that harbors genes encoding subunits of an ATP-sensitive cardiac potassium channel (*ABCC9* and *KCNJ8*). Single nucleotide polymorphisms above the black dotted line achieved a p value $< 10^{-8}$.

Of the positional genes, *ABCC9* and *KCNJ8* were the top candidates based on ontology and previous evidence for a role in inherited cardiac disorders. *ABCC9* and *KCNJ8* encode subunits of cardiac ATP-sensitive potassium (K_{ATP}) channels, SUR2 and Kir6.1, respectively [36,37]. These genes have been implicated in DCM, Cantú syndrome, atrial fibrillation, Brugada (J-wave) syndrome, and sudden death in infants and adults [7,8,38–47]. Exonic sequencing of *ABCC9* and *KCNJ8* in an affected dog revealed two *ABCC9* variants that were absent from controls (Table 1). One was a synonymous variant, *ABCC9* p.D1316=, that is a common SNP in dogs (rs852067132). The other was a missense variant, *ABCC9* p.R1186Q, that alters a highly conserved residue within the ABC transmembrane domain 2 (TMD2) and is predicted to be deleterious by in silico analyses (Figures 4 and S3, and Table 1). Missense3D predicted two structural changes as a result of this variant: buried charge replaced (replacement of a buried charged residue with an uncharged residue) and cavity altered (expansion of the cavity volume by 80 \AA^3). The p.R1186Q variant was not present in dbSNP *C. lupus familiaris* build 151 or the Dog Biomedical Variant Database Consortium database.




Figure 4. Representative Sanger sequencing electropherograms for wild-type, heterozygous, and homozygous affected genotypes for the *ABCC9* p.R1186Q variant (ENSCAFT00000043641.4 c.3557G > A) associated with sudden cardiac death in the young and dilated cardiomyopathy in a natural dog model.

Table 1. Exonic variants identified in *ABCC9* in a Manchester Terrier dog with sudden cardiac death in the young and dilated cardiomyopathy.

Genomic Alteration *	Protein Alteration †	PhyloP	PolyPhen-2 HumVar	Mut-Pred2	Allele Frequency dbSNP ‡	DBVDC
CFA27: g.21042635C > T	p.R1186Q	7.8	0.998	0.722 §	0	0
CFA27: g.21025527G > A	p.D1316=	1.7	NA	NA	0.34	0.30

DBVDC, Dog Biomedical Variant Database Consortium. * Genomic positions are based on the Dog10K_Boxer_Tasha/canFam6 assembly (GenBank assembly accession GCA_000002285.4). † Protein positions are based on transcript ENSCAFT00000043641.4 and UniProt J9NYX2. ‡ *C. lupus familiaris* build 151. § MutPred2 predicted three molecular mechanisms, including loss of allosteric site at R1186 (probability 0.28, $p = 0.0066$) and altered DNA binding (probability 0.19, $p = 0.03$, and altered transmembrane protein (probability 0.09, $p = 0.05$).

3.2. Validation of the Association between *ABCC9* p.R1186Q and SCDY/DCM

Additional dogs were recruited to determine population frequency and penetrance of *ABCC9* p.R1186Q in Manchester Terriers and a closely related breed, the English Toy Terrier, that is also affected by SCDY/DCM. Eight hundred and twenty-one dogs were genotyped, including 19 SCDY/DCM cases, 398 adult controls, 401 juvenile dogs with unknown phenotypes, and 3 adult dogs with hypertrophic cardiomyopathy. The variant was present in a homozygous state (100% allele frequency) in all SCDY/DCM cases. No control was homozygous for *ABCC9* p.R1186Q, but 69 heterozygous carriers were detected with a variant allele frequency of 0.08 in Manchester Terriers and 0.09 in English Toy Terriers. The three adult dogs (2, 6, and 8 years old) with hypertrophic cardiomyopathy were clear of the variant. The variant was present in a homozygous state in 9 of 401 juvenile dogs (<2 years of age) of undetermined phenotype. Three of these dogs died suddenly as puppies (i.e., SCDY, two at 7 weeks of age and one at 11 months), and four were euthanized (one at 2 months and three at 4 months of age); in these seven homozygous dogs, DCM was histologically confirmed on necropsy. The affected dog that was euthanized at 2 months of age underwent an echocardiogram and electrocardiogram shortly before death, and no abnormalities were detected. The two other homozygous dogs were lost to follow up; both dogs also reportedly had normal echocardiographic findings, one had a normal electrocardiogram, and the other had a brief run of sinus tachycardia (>300 bpm). In total,

all 26 dogs with SCDY/DCM and none of the 398 control dogs were homozygous for *ABCC9* p.R1186Q ($p = 4 \times 10^{-42}$), consistent with autosomal recessive inheritance with complete penetrance. As previously reported [20], cryptorchidism was common in male dogs with SCDY/DCM, with 10 of 15 males homozygous for *ABCC9* p.R1186Q having unilateral or bilateral cryptorchidism. Of the five other homozygous males, three were too young (≤ 2 months of age) to determine if the testes were going to descend, and two did not have information provided on the status of the testes.

3.3. Homologous *ABCC9* Variants in Human Databases

We next checked dbSNP *H. sapiens* build 155 to determine if a homologous variant exists in humans. *ABCC9* p.R1186Q is a rare variant in humans (rs776973456, allele frequency ≤ 0.0007), detected in American, European, and Korean populations. It has been previously reported in a heterozygous state in a human with restrictive cardiomyopathy that also had a heterozygous variant in *MHY7* (encoding β -myosin heavy chain) [48]. Another missense variant, p.R1186W (rs886049169), also exists at this residue in humans at lower frequency (allele frequency ≤ 0.000007). Both the p.R1186Q and p.R1186W variants are currently classified as having uncertain significance by ClinVar [49].

4. Discussion

Our results demonstrate that the p.R1186Q variant in the cardiac ATP-sensitive potassium channel subunit gene, *ABCC9*, is associated with SCDY/DCM in a natural canine model. Homozygosity for the p.R1186Q variant had complete penetrance for sudden death before two years of age. The current ClinGen clinical validity classification for the role of *ABCC9* in DCM is “limited” [11]. The striking disease association here strengthens the evidence for a causal role of *ABCC9* in SCDY and DCM.

The triple-risk model for sudden infant death syndrome includes three co-existing risk factors: (1) a vulnerable infant, (2) a critical developmental period, and (3) an exogenous stressor(s) [50]. Expression of *ABCC9* increases with the transition from fetal glycolytic metabolism to mitochondrial oxidative metabolism in the newborn heart [51]. Cardiomyocytes lacking functional *ABCC9* have reduced fatty acid oxidation and oxygen consumption and are unable to respond to cell stress [51]. Thus, the discovery of an *ABCC9* variant that causes SCDY/DCM, with death potentially triggered by physiologically stressful events, is in alignment with the triple-risk model. It is unknown whether antiarrhythmic drugs or other therapies during the critical development stage might prevent SCDY in puppies homozygous for the *ABCC9* p.R1186Q variant. In a Kir6.2 (another subunit of the cardiac K_{ATP} channel) knockout mouse model, calcium-channel blockade with verapamil reduced sudden death [52]. In humans, genotype-targeted therapies are emerging for prevention of sudden cardiac death in patients with genetic risk factors [53].

The *ABCC9* protein is a regulatory subunit of cardiac K_{ATP} channels and consists of two 6-helix transmembrane domains (TMD1 and TMD2), a 5-helix N-terminal domain (TMD0), and two nucleotide binding folds (NBF1 and NBF2) [54]. The SCDY/DCM associated p.R1186Q variant resides within TMD2. This variant was previously detected in a heterozygous state in a human with restrictive cardiomyopathy; however, the presence of a concurrent variant in *MYH7*, an established susceptibility gene for restrictive cardiomyopathy, complicated prediction of the role of the *ABCC9* variant in the cardiac phenotype of that patient [48,55]. A nearby rare variant in the TMD2, p.R1197C (rs778849288), has been identified in humans with sudden unexplained nocturnal death syndrome or DCM [7,47]. Another nearby variant, p.M1198I (rs199900459), was reported in a patient with left ventricular non-compaction cardiomyopathy [56]. The TMD2 is also a common site for gain of function variants causal for Cantú syndrome [42,43]. The pathogenicity of p.R1186Q is supported by the high conservation of the R1186 residue and its location in a hot spot for cardiac phenotypes. However, the absence of functional assays is a limitation of this study, and the specific effect of the variant on cardiac K_{ATP} channel function is unknown. The *ABCC9* subunit of the cardiac K_{ATP} channel regulates its inhibition by ATP, and this

inhibition is decreased by Cantú syndrome *ABCC9* variants, including those located in TMD2 [42]. Some of the *ABCC9* variants identified in human SCDY patients similarly exhibit reduced sensitivity to ATP inhibition [8]. The SCDY/DCM associated p.R1186Q variant identified here is predicted to cause structural changes to the protein, including replacement of a buried charge and expansion of cavity volume, which could alter ATP sensitivity or have other effects on channel function.

In addition to the cardiac phenotype, most affected male dogs were unilaterally or bilaterally cryptorchid. Cryptorchidism is not a reported phenotype of variants in *ABCC9* or the other genes residing in the risk haplotype [49]. However, hypertrophic cardiomyopathy and cryptorchidism are common features of RASopathies, such as LEOPARD syndrome, Noonan syndrome, Costello syndrome, and cardiofaciocutaneous syndrome [57], and pathway analysis of cryptorchidism candidate genes includes associations with “cardiac muscle contraction”, “dilated cardiomyopathy”, and “hypertrophic cardiomyopathy” [58]. Since only *ABCC9* and *KCNJ8* were selected for sequencing in this study, we cannot determine whether the reported *ABCC9* variant is the top candidate for cryptorchidism in the affected Manchester Terriers or if there is a more likely causal variant in a different gene that is present in linkage disequilibrium.

The present discovery adds to a growing list of shared susceptibility genes for sudden cardiac death and DCM between dogs and humans [59]. For example, variants in *KCNQ1* (potassium voltage-gated channel subfamily Q member 1) are one of the most common causes of long QT syndrome in humans, and a *KCNQ1* variant is associated with this syndrome in dogs [13,60]. The most common DCM susceptibility variant in humans, *TTN* (titin), is also a major underlying contributor to sudden cardiac death and DCM in dogs [6,14]. Other examples of shared susceptibility genes between these species include *PLN* (phospholamban), *RBM20* (RNA-binding motif protein 20), and *DMD* (dystrophin) [11,15,16,61–63]. In addition to strengthening pathogenicity evidence for known candidate genes in humans, studies in dogs have revealed novel susceptibility genes for sudden cardiac death, DCM, or both, such as *STRN* (striatin), *PDK4* (pyruvate dehydrogenase kinase 4), and *QIL1/MICOS13* (mitochondrial contact site and cristae organizing system subunit 13) [17–19]. The success of molecular autopsies for diagnosing genetic causes of sudden cardiac death depends on the comprehensiveness of the gene panel, the evidence level for the gene, and the ability to predict pathogenicity of specific variants. There are greater than 70 candidate genes for sudden cardiac death and greater than 40 for nonsyndromic DCM, but many lack definitive evidence to confirm their role in these diseases [10,11]. A study on results of panel testing of more than 200 genes in patients with inherited cardiomyopathies or channelopathies found that 61% of variants detected resided in genes with insufficient evidence to confirm disease association, and 70% of those were variants of unknown significance [64]. Data from dogs and other natural animal models of sudden cardiac death and DCM can contribute to evidence of gene associations with disease and variant pathogenicity and thereby hold value in improving the accuracy of molecular autopsies.

In conclusion, while the functional effect of the *ABCC9* p.R1186Q variant on cardiac K_{ATP} channels is undetermined, the results of this study strengthen the evidence that *ABCC9* is a susceptibility gene for sudden cardiac death and DCM in infants, children, and adults. The perfect correlation between homozygosity for p.R1186Q and SCDY/DCM in Manchester Terrier dogs adds to the *in silico* evidence that it is a pathogenic variant [65]. Genotype–phenotype association is often difficult to confirm for rare variants in humans. The results of this study demonstrate how spontaneous dog models can help validate disease associations for susceptibility variants and thus improve confidence in the clinical significance of homologous human variants. The discovery of the *ABCC9* p.R1186Q also enables genetic testing of breeding dogs to prevent affected puppies from being produced.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/genes14050988/s1>, Figure S1: Q-Q plot of the GWAS results; Figure S2: Plot of GWAS results for CFA27; Table S1: Top SNPs ($p < 10^{-8}$) associated with SCDY/DCM in a mixed model GWAS in Manchester Terrier dogs (12 cases and 36 controls); Table S2: Protein-coding genes residing in the critical region associated with SCDY/DCM in a mixed model GWAS in Manchester Terrier dogs; Table S3: PCR primers used for sequencing of ABCC9 and KCNJ8 coding exons. Figure S3: Location of the p.R1186Q variant in the predicted ABCC9 protein structure.

Author Contributions: Conceptualization, E.F., K.M. and P.H.; methodology, E.F., N.T. and K.M.; formal analysis, E.F., N.T., K.M. and S.L.; investigation, E.F., K.M., S.M., M.A., M.S. and P.H.; writing—original draft preparation, E.F.; writing—review and editing, E.F., N.T., K.M., S.M., M.A., S.L., M.S. and P.H.; funding acquisition, E.F. and K.M. All authors have read and agreed to the published version of the manuscript.

Funding: Funding for this research was provided through a donation from the American Manchester Terrier Club. S.L. was supported in part by a National Institutes of Health (NIH) Office of the Director Short-Term Institutional Research Training Grant, T35OD011118. E.F. was supported in part by an NIH Office of the Director Special Emphasis Research Career Award, K01OD019912, and an NIH National Center for Advancing Translational Sciences grant, UL1TR002494. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Institutional Review Board Statement: The study protocol was approved by the University of Minnesota Institutional Animal Care and Use Committee (protocol ID 1509-33019A, approved 30 September 2015). Written informed consent was obtained from dog owners.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data that support the findings of this study are either included in the published article and its supplementary information files or available from the corresponding author upon reasonable request.

Acknowledgments: We thank the dog owners, breeders, and veterinarians that participated in this research.

Conflicts of Interest: E.F. and K.M. are members of the University of Minnesota Canine Genetics Laboratory, which offers genetic testing for the ABCC9 variant in dogs; a portion of proceeds supports ongoing research for the laboratory. The other authors (N.T., S.M., S.L., M.A., M.S. and P.H.) declare they have no conflict of interest.

References

1. Tester, D.J.; Mederios-Domingo, A.; Will, M.L.; Haglund, C.M.; Ackerman, M.J. Cardiac channel molecular autopsy: Insights from 173 consecutive cases of autopsy-negative sudden unexplained death referred for postmortem genetic testing. *Mayo Clin. Proc.* **2012**, *87*, 524–539. [[CrossRef](#)] [[PubMed](#)]
2. Bagnall, R.D.; Weintraub, R.G.; Ingles, J.; Dufrou, J.; Yeates, L.; Lam, L.; Davis, A.M.; Thompson, T.; Connell, V.; Wallace, J.; et al. A prospective study of sudden cardiac death among children and young adults. *N. Engl. J. Med.* **2016**, *374*, 2441–2452. [[CrossRef](#)] [[PubMed](#)]
3. Hertz, C.L.; Christiansen, S.L.; Ferrero-Miliani, L.; Dahl, M.; Weeke, P.E.; LuCamp; Ottesen, G.L.; Frank-Hansen, R.; Bundgaard, H.; Morling, N. Next-generation sequencing of 100 candidate genes in young victims of suspected sudden cardiac death with structural abnormalities of the heart. *Int. J. Legal Med.* **2016**, *130*, 91–102. [[CrossRef](#)] [[PubMed](#)]
4. Dewar, L.J.; Alcaide, M.; Fornika, D.; D'Amata, L.; Shafaatalab, S.; Stevens, C.M.; Balachandra, T.; Phillips, S.M.; Sanatani, S.; Morin, R.D.; et al. Investigating the genetic causes of sudden unexpected death in children through targeted next-generation sequencing analysis. *Circ. Cardiovasc. Genet.* **2017**, *10*, e001738. [[CrossRef](#)] [[PubMed](#)]
5. Larsen, M.K.; Christiansen, S.L.; Hertz, C.L.; Frank-Hansen, R.; Jensen, H.K.; Banner, J.; Morling, N. Targeted molecular genetic testing in young sudden cardiac death victims from Western Denmark. *Int. J. Legal Med.* **2020**, *134*, 111–121. [[CrossRef](#)]
6. Mazzarotto, F.; Tayal, U.; Buchan, R.J.; Midwinter, W.; Wilk, A.; Whiffin, N.; Govind, R.; Mazaika, E.; de Marvao, A.; Dawes, T.J.W.; et al. Reevaluating the genetic contribution of monogenic dilated cardiomyopathy. *Circulation* **2020**, *141*, 387–398. [[CrossRef](#)]
7. Zhang, L.; Tester, D.J.; Lang, D.; Chen, Y.; Zheng, J.; Gao, R.; Corliss, R.F.; Tang, S.; Kyle, J.W.; Liu, C.; et al. Does sudden unexplained nocturnal death syndrome remain the autopsy negative disorder: A gross, microscopic, and molecular autopsy investigation in Southern China. *Mayo Clin. Proc.* **2016**, *91*, 1503–1514. [[CrossRef](#)]
8. Subbotina, E.; Yang, H.Q.; Gando, I.; Williams, N.; Sampson, B.A.; Tang, Y.; Coetzee, W.A. Functional characterization of ABCC9 variants identified in sudden unexpected natural death. *Forensic Sci. Int.* **2019**, *298*, 80–87. [[CrossRef](#)]

9. Hershberger, R.E.; Cowan, J.; Jordan, E.; Kinnamon, D.D. The complex and diverse genetic architecture of dilated cardiomyopathy. *Circ. Res.* **2021**, *128*, 1514–1532. [[CrossRef](#)]
10. Fan, L.; Yin, P.; Xu, Z. The genetic basis of sudden death in young people—Cardiac and non-cardiac. *Gene* **2022**, *810*, 146067. [[CrossRef](#)]
11. Jordan, E.; Peterson, L.; Ai, T.; Asatryan, B.; Bronicki, L.; Brown, E.; Celeghin, R.; Edwards, M.; Fan, J.; Ingles, J.; et al. Evidence-based assessment of genes in dilated cardiomyopathy. *Circulation* **2021**, *144*, 7–9. [[CrossRef](#)]
12. Shearin, A.L.; Ostrander, E.A. Leading the way: Canine models of genomics and disease. *Dis. Model. Mech.* **2010**, *3*, 27–34. [[CrossRef](#)]
13. Ware, W.A.; Reina-Doreste, Y.; Stern, J.A.; Meurs, K.M. Sudden death associated with QT interval prolongation and KCNQ1 gene mutation in a family of English Springer Spaniels. *J. Vet. Intern. Med.* **2015**, *29*, 561–568. [[CrossRef](#)]
14. Meurs, K.M.; Friedenber, S.G.; Kolb, J.; Saripalli, C.; Tonino, P.; Woodruff, K.; Olby, N.J.; Keene, B.W.; Adin, D.B.; Yost, O.L.; et al. A missense variant in the titin gene in Doberman pinscher dogs with familial dilated cardiomyopathy and sudden cardiac death. *Hum. Genet.* **2019**, *138*, 515–524. [[CrossRef](#)]
15. Yost, O.; Friedenber, S.G.; Jesty, S.A.; Olby, N.J.; Meurs, K.M. The R9H phospholamban mutation is associated with highly penetrant dilated cardiomyopathy and sudden death in a spontaneous canine model. *Gene* **2019**, *20*, 118–122. [[CrossRef](#)]
16. Leach, S.B.; Briggs, M.; Hansen, L.; Johnson, G.S. Prevalence, geographic distribution, and impact on lifespan of a dilated cardiomyopathy-associated RNA-binding motif protein 20 variant in genotyped dogs. *J. Vet. Cardiol.* **2022**, *40*, 119–125. [[CrossRef](#)]
17. Meurs, K.M.; Mauceli, E.; Lahmers, S.; Acland, G.M.; White, S.N.; Lindblad-Toh, K. Genome-wide association identifies a deletion in the 3' untranslated region of striatin in a canine model of arrhythmogenic right ventricular cardiomyopathy. *Hum. Genet.* **2010**, *128*, 315–324. [[CrossRef](#)]
18. Meurs, K.M.; Lahmers, S.; Keene, B.W.; White, S.N.; Oyama, M.A.; Mauceli, E.; Lindblad-Toh, K. A splice site mutation in a gene encoding for PDK4, a mitochondrial protein, is associated with the development of dilated cardiomyopathy in the Doberman pinscher. *Hum. Genet.* **2012**, *131*, 1319–1325. [[CrossRef](#)]
19. Meurs, K.M.; Friedenber, S.G.; Olby, N.J.; Condit, J.; Weidman, J.; Rosenthal, S.; Shelton, D. A QIL variant associated with ventricular arrhythmias and sudden cardiac death in the juvenile Rhodesian Ridgeback dog. *Genes* **2019**, *10*, 168. [[CrossRef](#)]
20. Legge, C.H.; López, A.; Hanna, P.; Côté, E.; Hare, E.; Martinson, S.A. Histological characterization of dilated cardiomyopathy in the juvenile toy Manchester terrier. *Vet. Pathol.* **2013**, *50*, 1043–1052. [[CrossRef](#)]
21. Purcell, S.; Neale, B.; Todd-Brown, K.; Thomas, L.; Ferreira, M.A.R.; Bender, D.; Maller, J.; Sklar, P.; de Bakker, P.I.W.; Daly, M.J.; et al. PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses. *Am. J. Hum. Genet.* **2007**, *81*, 559–575. [[CrossRef](#)] [[PubMed](#)]
22. Zhou, X.; Stephens, M. Genome-wide efficient mixed-model analysis for association studies. *Nat. Genet.* **2012**, *44*, 821–824. [[CrossRef](#)] [[PubMed](#)]
23. Scheet, P.; Stephens, M. A fast and flexible statistical model for large-scale population genotype data: Applications to inferring missing genotypes and haplotypic phase. *Am. J. Hum. Genet.* **2006**, *78*, 629–644. [[CrossRef](#)] [[PubMed](#)]
24. Kent, W.J. BLAT—The BLAST-like alignment tool. *Genome Res.* **2002**, *12*, 656–664. [[CrossRef](#)] [[PubMed](#)]
25. Jagannathan, V.; Hitte, C.; Kidd, J.M.; Masterson, P.; Murphy, T.D.; Emery, S.; Davis, B.; Buckley, R.M.; Liu, Y.H.; Zhang, X.Q.; et al. Dog10K_Boxer_Tasha_1.0: A long-read assembly of the dog reference genome. *Genes* **2021**, *12*, 847. [[CrossRef](#)]
26. Sherry, S.T.; Ward, M.; Sirotkin, K. dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. *Genome Res.* **1999**, *9*, 677–679. [[CrossRef](#)]
27. Jagannathan, V.; Drögemüller, C.; Leeb, T.; Dog Biomedical Variant Database Consortium (DBVDC). A comprehensive biomedical variant catalogue based on whole genome sequences of 582 dogs and eight wolves. *Anim. Genet.* **2019**, *50*, 695–704. [[CrossRef](#)]
28. Adzhubei, I.A.; Schmidt, S.; Peshkin, L.; Ramensky, V.E.; Gerasimova, A.; Bork, P.; Kondrashov, A.S.; Sunyaev, S.R. A method and server for predicting damaging missense mutations. *Nat. Methods* **2010**, *7*, 248–249. [[CrossRef](#)]
29. Pejaver, V.; Urresti, J.; Lugo-Martinez, J.; Pagel, K.A.; Lin, G.N.; Nam, H.J.; Mort, M.; Cooper, D.N.; Sebat, J.; Iakoucheva, L.M.; et al. Inferring the molecular and phenotypic impact of amino acid variants with MutPred2. *Nat. Commun.* **2020**, *11*, 5918. [[CrossRef](#)]
30. Kent, W.J.; Sugnet, C.W.; Furey, T.S.; Roskin, K.M.; Pringle, T.H.; Zahler, A.M.; Haussler, D. The human genome browser at UCSC. *Genome Res.* **2002**, *12*, 996–1006. [[CrossRef](#)]
31. Pollard, K.S.; Hubisz, M.J.; Rosenbloom, K.R.; Siepel, A. Detection of nonneutral substitution rates on mammalian phylogenies. *Genome Res.* **2010**, *20*, 110–121. [[CrossRef](#)]
32. Jumper, J.; Evans, R.; Pritzel, A.; Green, T.; Figurnov, M.; Ronneberger, O.; Tunyasuvunakool, K.; Bates, R.; Židek, A.; Potapenko, A.; et al. Highly accurate protein structure prediction with AlphaFold. *Nature* **2021**, *596*, 583–589. [[CrossRef](#)]
33. Varadi, M.; Anyango, S.; Deshpande, M.; Nair, S.; Natassia, C.; Yoranova, G.; Yuan, D.; Stroe, O.; Wood, G.; Laydon, A.; et al. AlphaFold Protein Structure Database: Massively expanding the structural coverage of protein-sequence space with high-accuracy models. *Nucleic Acids Res.* **2022**, *50*, D439–D444. [[CrossRef](#)]
34. The PyMOL Molecular Graphics System, Version 2.5 Schrödinger, LLC. Available online: <https://pymol.org/2/> (accessed on 4 April 2023).
35. Ittisoponpisan, S.; Islam, S.A.; Khanna, T.; Alhuzimi, E.; David, A.; Sternberg, M.J.E. Can predicted protein 3D structures provide reliable insights into whether missense variants are disease associated? *J. Mol. Biol.* **2019**, *431*, 2197–2212. [[CrossRef](#)]

36. Inagaki, N.; Tsuura, Y.; Namba, N.; Masuda, K.; Gono, T.; Horie, M.; Seino, Y.; Mizuta, M.; Seino, S. Cloning and functional characterization of a novel ATP-sensitive potassium channel ubiquitously expressed in rat tissues, including pancreatic islets, pituitary, skeletal muscle and heart. *J. Biol. Chem.* **1995**, *270*, 5691–5694. [[CrossRef](#)]
37. Inagaki, N.; Gono, T.; Clement, J.P.; Wang, C.Z.; Aguilar-Bryan, L.; Bryan, J.; Seino, S. A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K⁺ channels. *Neuron* **1996**, *16*, 1011–1017. [[CrossRef](#)]
38. Bienengraeber, M.; Olson, T.M.; Selivanov, V.A.; Kathmann, E.C.; O’Cochlain, F.; Gao, F.; Karger, A.B.; Ballew, J.D.; Hodgson, D.M.; Zingman, L.V.; et al. ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. *Nat. Genet.* **2004**, *36*, 382–387. [[CrossRef](#)]
39. Olson, T.M.; Alekseev, A.E.; Moreau, C.; Liu, X.K.; Zingman, L.V.; Miki, T.; Seino, S.; Asirvatham, S.J.; Jahangir, A.; Terzic, A. KATP channel mutation confers risk for vein of Marshall adrenergic atrial fibrillation. *Nat. Clin. Pract. Cardiovasc. Med.* **2007**, *4*, 110–116. [[CrossRef](#)]
40. Medeiros-Domingo, A.; Tan, B.H.; Crotti, L.; Tester, D.J.; Eckhardt, L.; Cuoretti, A.; Kroboth, S.L.; Song, C.; Zhou, Q.; Kopp, D.; et al. Gain-of-function mutation S422L in the KCNJ8-encoded cardiac K(ATP) channel Kir6.1 as a pathogenic substrate for J-wave syndromes. *Heart Rhythm.* **2010**, *7*, 1466–1471. [[CrossRef](#)]
41. Tester, D.J.; Tan, B.H.; Medeiros-Domingo, A.; Song, C.; Makielski, J.C.; Ackerman, M.J. Loss-of-function mutations in the KCNJ8-encoded Kir6.1 K(ATP) channel and sudden infant death syndrome. *Circ. Cardiovasc. Genet.* **2011**, *4*, 510–515. [[CrossRef](#)]
42. Harakalova, M.; van Harsseel, J.J.T.; Terhal, P.A.; van Lieshout, S.; Duran, K.; Renkens, I.; Amor, D.J.; Wilson, L.C.; Kirk, E.P.; Turner, C.L.S.; et al. Dominant missense mutations in ABCC9 cause Cantú syndrome. *Nat. Genet.* **2012**, *44*, 793–796. [[CrossRef](#)] [[PubMed](#)]
43. van Bon, B.W.M.; Gilissen, C.; Grange, D.K.; Hennekam, R.C.M.; Kayserili, H.; Engels, H.; Reutter, H.; Ostergaard, J.R.; Morava, E.; Tsiakas, K.; et al. Cantú syndrome is caused by mutations in ABCC9. *Am. J. Hum. Genet.* **2012**, *90*, 1094–1101. [[CrossRef](#)] [[PubMed](#)]
44. Delaney, J.T.; Muhammad, R.; Blair, M.A.; Kor, K.; Fish, F.A.; Roden, D.M.; Darbar, D. A KCNJ8 mutation associated with early repolarization and atrial fibrillation. *Europace* **2012**, *14*, 1428–1432. [[CrossRef](#)]
45. Hu, D.; Barajas-Martínez, H.; Terzic, A.; Park, S.; Pfeiffer, R.; Burashnikov, E.; Wu, Y.; Borggreffe, M.; Veltmann, C.; Schimpf, R.; et al. ABCC9 is a novel Brugada and early repolarization syndrome susceptibility gene. *Int. J. Cardiol.* **2014**, *171*, 431–442. [[CrossRef](#)] [[PubMed](#)]
46. Carnevale, A.; Rosas-Madrigal, S.; Rosendo-Gutiérrez, R.; López-Mora, E.; Romero-Hidalgo, S.; Avila-Vazzini, N.; Jacobo-Albavera, L.; Domínguez-Pérez, M.; Vargas-Alarcón, G.; Pérez-Villatoro, F.; et al. Genomic study of dilated cardiomyopathy in a group of Mexican patients using site-directed next generation sequencing. *Mol. Genet. Genomic Med.* **2020**, *8*, e1504. [[CrossRef](#)]
47. Shen, C.; Xu, L.; Sun, X.; Sun, A.; Ge, J. Genetic variants in Chinese patients with sporadic dilated cardiomyopathy: A cross-sectional study. *Ann. Transl. Med.* **2022**, *10*, 129. [[CrossRef](#)]
48. Neagoe, O.; Ciobanu, A.; Diaconu, R.; Mirea, O.; Donoiu, I.; Militaru, C. A rare case of familial restrictive cardiomyopathy, with mutations in MYH7 and ABCC9 genes. *Discoveries* **2019**, *30*, e99. [[CrossRef](#)]
49. Landrum, M.J.; Lee, J.M.; Benson, M.; Brown, G.R.; Chao, C.; Chitipiralla, S.; Gu, B.; Hart, J.; Hoffman, D.; Jang, W.; et al. ClinVar: Improving access to variant interpretations and supporting evidence. *Nucleic Acids Res.* **2018**, *46*, D1062–D1067. [[CrossRef](#)]
50. Filiano, J.J.; Kinney, H.C. A perspective on neuropathologic findings in victims of the sudden infant death syndrome: The triple-risk model. *Biol. Neonate* **1994**, *65*, 194–197. [[CrossRef](#)]
51. Fahrenbach, J.P.; Stoller, D.; Kim, G.; Aggarwal, N.; Yerokun, B.; Earley, J.U.; Hadhazy, M.; Shi, N.Q.; Makielski, J.C.; McNally, E.M. Abcc9 is required for the transition to oxidative metabolism in the newborn heart. *FASEB J.* **2014**, *28*, 2804–2815. [[CrossRef](#)]
52. Zingman, L.V.; Hodgson, D.M.; Bast, P.H.; Kane, G.C.; Perez-Terzic, C.; Gumina, R.J.; Pucar, D.; Bienengraeber, M.; Dzeja, P.P.; Miki, T.; et al. Kir6.2 is required for adaptation to stress. *Proc. Natl. Acad. Sci. USA* **2022**, *99*, 13278–13283. [[CrossRef](#)]
53. Orphanou, N.; Papatheodorou, E.; Anastasakis, A. Dilated cardiomyopathy in the era of precision medicine: Latest concepts and developments. *Heart Fail. Rev.* **2022**, *27*, 1173–1191. [[CrossRef](#)]
54. Nichols, C.G.; Singh, G.K.; Grange, D.K. KATP channels and cardiovascular disease: Suddenly a syndrome. *Circ. Res.* **2013**, *112*, 1059–1072. [[CrossRef](#)]
55. Brodehl, A.; Gerull, B. Genetic insights into primary restrictive cardiomyopathy. *J. Clin. Med.* **2022**, *11*, 2094. [[CrossRef](#)]
56. Waldmüller, S.; Schroeder, C.; Sturm, M.; Scheffold, T.; Imbrich, K.; Junker, S.; Frische, C.; Hofbeck, M.; Bauer, P.; Bonin, M.; et al. Targeted 46-gene and clinical exome sequencing for mutations causing cardiomyopathies. *Mol. Cell. Probes* **2015**, *29*, 308–314. [[CrossRef](#)]
57. Digilio, M.C.; Lepri, F.; Baban, A.; Dentici, M.L.; Versacci, P.; Capolino, R.; Ferese, R.; De Luca, A.; Tartaglia, M.; Marino, B.; et al. RASopathies: Clinical diagnosis in the first year of life. *Mol. Syndromol.* **2011**, *1*, 282–289. [[CrossRef](#)]
58. Cannistraci, C.V.; Ogorevc, J.; Zorc, M.; Ravasi, T.; Dovc, P.; Kunej, T. Pivotal role of the muscle-contraction pathway in cryptorchidism and evidence for genomic connections with cardiomyopathy pathways in RASopathies. *BMC Med. Genom.* **2013**, *6*, 5. [[CrossRef](#)]
59. Gaar-Humphreys, K.R.; Spanjersberg, T.C.F.; Santarelli, G.; Grinwis, G.C.M.; Szatmári, V.; Roelen, B.A.; Vink, A.; van Tinen, J.P.; Asselbergs, F.W.; Fieten, H.; et al. Genetic basis of dilated cardiomyopathy in dogs and its potential as a bidirectional model. *Animals* **2022**, *12*, 1679. [[CrossRef](#)]

60. Wallace, E.; Howard, L.; Liu, M.; O'Brien, T.; Ward, D.; Shen, S.; Prendiville, T. Long QT syndrome: Genetics and future perspective. *Pediatr. Cardiol.* **2019**, *40*, 1419–1430. [[CrossRef](#)]
61. Haghghi, K.; Kolokathis, F.; Gramolini, A.O.; Waggoner, J.R.; Pater, L.; Lynch, R.A.; Fan, G.C.; Tsiapras, D.; Parekh, R.R.; Dorn, G.W., 2nd; et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 1388–1393. [[CrossRef](#)]
62. Schatzberg, S.J.; Olby, N.J.; Breen, M.; Anderson, L.V.B.; Langford, C.F.; Dickens, H.F.; Wilton, S.D.; Zeiss, C.J.; Binns, M.M.; Kornegay, J.N.; et al. Molecular analysis of a spontaneous dystrophin 'knockout' dog. *Neuromuscul. Disord.* **1999**, *9*, 289–295. [[CrossRef](#)] [[PubMed](#)]
63. Nigro, G.; Comi, L.I.; Politano, L.; Bain, R.J. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. *Int. J. Cardiol.* **1990**, *26*, 271–277. [[CrossRef](#)] [[PubMed](#)]
64. Mazzaccara, C.; Lombardi, R.; Mirra, B.; Barretta, F.; Esposito, M.V.; Uomo, F.; Caiazza, M.; Monda, E.; Losi, M.A.; Limongelli, G.; et al. Next-generation sequencing gene panels in inheritable cardiomyopathies and channelopathies: Prevalence of pathogenic variants and variants of unknown significance in uncommon genes. *Biomolecules* **2022**, *12*, 1417. [[CrossRef](#)] [[PubMed](#)]
65. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med.* **2015**, *17*, 405–424. [[CrossRef](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.